2.) Nanoparticle-based drug delivery Flashcards Preview

#FME - Nanotechnology and Advanced Materials > 2.) Nanoparticle-based drug delivery > Flashcards

Flashcards in 2.) Nanoparticle-based drug delivery Deck (25)
Loading flashcards...
1

Rank the following drug types in size: sMW drugs, proteins, nucleic acids.

1.) sMW drugs (1 nm)
2.) Nucleic acids
3.) Proteins 10nm (mAb = 160 kDa)

2

What are some limitations with traditional drugs for drug delivery?

Limitations of sMW, proteins and nucleic acids:
- Low cell uptake (if drug requires internalisation)
- Short blood circulation time; 10 minutes for DNA (exception: mAbs)
- Rapid degradation in physiological fluids
- Lack of cell specificity (e.g. chemotherapy)

3

What are the two different types of nanoparticle delivery systems?

- Viral vectors (majority of gene therapies)
- Non-viral vectors

4

Name some examples of viral vectors (for nanoparticle drug delivery).

- Adenoviruses (nonenveloped, without outer lipid bilayer)
- Adeno-associted viruses
- Retroviruses
- Lentiviruses (for non-dividing cells)

5

What are the advantages and disadvantages of using viral vectors for nanoparticle drug delivery?

Advantages:
- Efficient cell uptake (see: gene therapies)
- Endosomal escape

Disadvantages:
- Immunogenicity (potential immune response)
- Low cell specificty
- Limited packaging capacity (genetic material able to be loaded into virus)
- DIfficult to produce: purification, concentrated, storage requirements, small scale etc

6

Name some examples of non-viral vectors (for nanoparticle drug delivery).

- Liposome
- Polymerosomes
- Cationic polymers
- Cell penetrating peptides
- Degradable polymer microparticles/nanoparticles
- Magnetic nanoparticles

7

What advantages are associated with non-viral vectors for nanoparticle drug delivery?

See - disadvantages of viral vectors:
- Lower immunogenicity
- Patients do not have pre-existing immunity (patient may have immune response to viral vector w/pre-existing immunity)
- Larger payloads (more genetic material)
- Easier to synthethise

8

What is a liposome? What are they commonly made of?

- Amphiphilic molecule mimicking cell membrane: hydrophilic head (facing out to water) and hydrophobic fatty tails
- Self assembly to bilayer structure (driven thermodynamically)
>>> Commonly made up of DOTMA (, N-[1-(2,3-
dioleyloxy)propyl)-N,N,N-trimethylammonium chloride)

9

What are polymersomes?

- Polymeric versions of liposomes
- Made up of amphiphilic polymers
- Similar to liposomes (amphiphilic nature)

10

What are cationic polymers?

Example:
- Polyethylenimine (PEI) for delivering nucleic acids
- Positively charged (cationic) PEI can condense negatively charged nucleic acids (negative phosphate backbone) to form polyplexes [spherical/doughnut-shaped nanoparticulate complexes)
- Positive charge also helps binding of polyplexes to cell membrane (which is negatively charged)
>>> It is an electrostatic interaction between polymer and nucleic acid

11

What are cell-penetrating peptides?

CPPs are similar to cationic polymers:
- Utilises macropinocytosis: a v. efficient variant of endocytosis as mechanism of entering cells
- Origin: shown that the TAT protein (transactivator of transcription) protein from HIV virus could directly enter cells
- Examples of CPP: octa-arginine (8R) and poly(L-lysine) [PLL]

12

What are degradable polymer micro/nanoparticles?

- Solid, hydrolytically degradable particles
- Degradation rate controls release rate of drug: days/months timescale of delivery (M/R profile)
- Examples: PLGA (poly lactic-co-glycolic acid)

13

What are the advantages of using degradable micro/nanoparticles?

- Long-term delivery (days or longer)
- Can alter and control drug PK by enabling sustained release

14

Describe a method of making drug-loaded nanoparticles from polymers?

Double emulsion method (W/O/W):
E.g.
- PLGA polymer is dissolved in organic solvent (dichloroethane, CH2Cl2) to form oil phase
- This is added to a cisplatin solution (dissolved in water) which is the water phase
- Sonification/mechanical agitation of the two allows dispersion of water phase in oil (W/O phase)
- W/O phase is poured into more water, with a surfactant added (PVA - polyvinyl alcohol) to stabilise dispersion
- End result = drug in water phase is encapsulated in oil phase which is in water phase solution
>>> Evaporation of organic solvent (CH2Cl2) = exposes solid drug (cisplatin)

15

What are magnetic nanoparticles? How can they be applied therapeutically?

- Nanoparticles made of iron (II, III) oxide commonly (made via chemical coprecipitation)
- Drug loaded surface coating can then be applied onto magnetic particles (e.g. PEG polymer, such as Doxorubicin)
- Can then respond to external magnetic field = magnetic field-guided delivery of drug to target, as well as allowing tracking of where drug is going (e.g. to tumour?)

16

What are the advantages of magnetic field-guided delivery in tumour targeting?

- Nanoparticles larger than 10nM usually cannot diffuse through normal/healthy endothelium (via small vascular pores)
- Leaky vasculature of tumours allow nanoparticles of up to 700nM to penetrate the endothelium
>>> External magnetic field facilitates delivery of magnetic nanoparticle to tumour site, increasing amount of drug delivered/less wastage elsewhere and off-target effects

17

What strategies are availible to increase serum half-life?

- Fc fusion proteins
- PEGylation

18

How do Fc fusion proteins increase serum half-life?

Fragment crystallisable fusion proteins:
- Made via DNA recombinant proteins
- Conjugate with peptide/protein drug molecules to endow with immunoglobulin-like property of long serum half-life (days-weeks)
- Does this by utilising the neonatal Fc receptor recycling pathway

19

How does PEGylation increase serum half-life?

Polyethylene glycol:
- Conjugation with v. hydrophilic (oxygen backbone) to drug (e.g. protein) = high hydration (water solvation layer) which increases hydrodynamic radius of the conjugate, reducing renal filtration
- PEG layer is 5-10x size of the protein itself
- Prevents uptake and clearance by mononuclear phagocytes (e.g. macrophages)
- Decreases formation of neutralising Ab against a protein by masking antigen sites
- Protection from proteolytic enzymes e.g. trypsin, chymotrypsin, proteases

20

What are the drawbacks/disadvantages of using PEGylation to increase serum half-life?

- Steric interference can reduce activity and binding affinity
- Protein is shielded from target as well as enzymes/Abs/phagocytes etc

21

How can we increase cell specificity?

Via antibody-drug conjugates:
- Antibody is linked to drug via linker
- Antibody conveys specificity to particular cell

22

How can antibody-drug conjugates be optimised for cell specificity?

- Better choices of target antigen and antibody
- Development of more potent drugs
- Development of linkers with greater stability

23

What are the three types of endocytosis, and their distinguishing features?

Phagocytosis:
- Big particles > 500nM
- Engulfed to form phagosome (internal compartment)
- E.g. bacteria
- Major endocytosis pathway

Pinocytosis:
- Smaller molecules suspended in extracellular fluid surrounding cells brought into the cell
- Via budding off of vesicle from the plasma membrane

Receptor-mediated endocytosis:
- Inward budding similar to pinocytosis but involving protein receptor sites on the plasma membrane (to metabolites, hormones etc)
- E.g. steroid receptors

24

What is endosomal escape, and why is it beneficial?

What if it does not occur?

- Once drug is internalised (endocytosis) it is encapsulated in the endosome
- Escape from endosome desired so drug can reach intracellular target sites e.g. in the cytosol, or the nucleus for DNA
>>> Viruses can either fuse their viral envelope with the phospholipid bilayer, or lyse the lipid membrane or generate a pore through it

- The endosome will eventually be degraded by the lysosome (degradative enzymes enclosed within)

25

What are the two parameters/formulas that dictate drug loading into nanoparticles?

Drug loading efficiency =
(Drug added - free un-encapsultated drug)/drug added

Loading capacity =
(Encapsulated drug/nanoparticle mass) x 100